報價延遲最少15分鐘:2025/09/16 09:48 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
26.72 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.75/3.34
|
|
企業價值
1.64B
|
| 資產負債 |
|
每股賬面淨值
16.86
|
| 現金流量 |
|
現金流量率
0.11
|
| 損益表 |
|
收益
700.97M
|
|
每股收益
14.82
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/09/16 09:48 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee. |
